Recruiting

Vaccine to prevent pancreatic cancer in high-risk patients

Plain-English translation of NCT05013216 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a vaccine called a mutant KRAS peptide vaccine, designed to help prevent pancreatic cancer in people at high risk. The vaccine works by training your immune system to recognize and fight abnormal cells before they become cancer. Researchers want to make sure the vaccine is safe and that it successfully activates your body's natural defenses.

Pancreatic cancer is very difficult to treat, especially when caught late. This study exists because people with a strong family history of pancreatic cancer, genetic mutations, or imaging signs of precancerous changes need new prevention options beyond just watching and waiting.

Do you qualify?

You likely qualify if…

you are at least 40–50 years old (depending on your risk category) or are 10 years younger than the youngest relative in your family who had pancreatic cancer
you have a family history of pancreatic cancer with two or more relatives affected, or you carry a known genetic mutation linked to pancreatic cancer risk (such as BRCA2, PALB2, p16, or Lynch syndrome)
you have had imaging tests (CT, MRI, or endoscopic ultrasound) that showed a pancreatic abnormality, such as a cyst or other concerning changes
you have adequate organ and bone marrow function based on standard blood tests
you are able to understand the study and willing to sign an informed consent form

You likely don't qualify if…

you have already been diagnosed with pancreatic cancer or other active cancers
you have a medical condition that severely weakens your immune system
you are unable to attend the required study visits and follow-up appointments
you have had an allergic reaction to vaccine components or similar treatments in the past

What participation looks like

You will attend a screening visit to confirm you meet the study requirements, then receive the vaccine during a treatment phase. After that, you'll have follow-up visits to monitor your health and immune response. The study includes an option to continue with annual check-up visits for several years after your last vaccine dose, allowing researchers to track how well the vaccine works over time.

AI-generated summary from trial data · Jul 4, 2026 · Not medical advice

Trial locations(1 site)

United States

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Vaccine to prevent pancreatic cancer in high-risk patients

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)

Key details

Contact the research team directly

Interested in joining?